Table 1 Patient characteristics
Number (%) | Number in those with clinical benefit (%) | Number in those without clinical benefit (%) | P | |
|---|---|---|---|---|
Gender | ||||
Male | 31 (91.2) | 15 (88.2) | 16 (94.1) | 0.54 |
Female | 3 (8.8) | 2 (11.8) | 1 (5.9) | |
Age | ||||
< 65 | 22 (64.7) | 11 (17.7) | 11 (17.7) | 1.00 |
≥ 65 | 12 (35.3) | 6 (35.3) | 6 (35.3) | |
Race | ||||
White | 25 (73.6) | 11 (64.7) | 14 (82.4) | 0.49 |
Black | 6 (17.7) | 4 (23.5) | 2 (11.8) | |
Asian | 2 (5.9) | 1 (5.9) | 1 (5.9) | |
Hispanic | 1 (2.9) | 1 (5.9) | 0 (0) | |
Smoking history | ||||
Yes | 24 (70.6) | 11 (64.7) | 13 (76.5) | 0.45 |
No | 10 (29.4) | 6 (35.3) | 4 (23.5) | |
ECOG | ||||
0 or 1 | 31 (91.2) | 15 (88.2) | 16 (94.1) | 0.54 |
≥ 2 | 3 (8.8) | 2 (11.8) | 1 (5.9) | |
Primary tumor location | ||||
Nasopharynx | 5 (14.7) | 4 (23.5) | 1 (5.9) | 0.51 |
Oral cavity | 5 (14.7) | 3 (17.6) | 2 (11.8) | |
Oropharynx | 15 (44.1) | 7 (41.2) | 8 (47.1) | |
Hypopharynx | 1 (2.9) | 0 (0) | 1 (5.9) | |
Larynx | 6 (17.7) | 2 (11.8) | 4 (23.5) | |
Sinus | 2 (5.9) | 1 (5.9) | 1 (5.9) | |
Virus association | ||||
EBV | 5 (14.7) | 4 (23.5) | 1 (5.9) | 0.28 |
HPV/p16 | 14 (41.2) | 7 (41.2) | 7 (41.2) | |
None | 15 (44.1) | 6 (35.3) | 9 (52.9) | |
Number of prior systemic therapy regimens | ||||
0 or 1 | 18 (52.9) | 11 (64.7) | 7 (41.2) | 0.17 |
2 or more | 16 (47.1) | 6 (35.3) | 10 (58.8) | |
PD-1 Inhibitor | ||||
Nivolumab | 16 (47.1) | 9 (52.9) | 7 (41.2) | 0.49 |
Pembrolizumab | 18 (52.9) | 8 (47.1) | 10 (58.8) | |